PATENT CLAIM ANALYSIS

Application Number: 16289165
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "278000"]

Abstract:
The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.

Claim (Index 48):
The formulation of  claim 38 , wherein the formulation contains 20 milligrams of trospium chloride.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 99.0
- Lexical Diversity: 1.69091
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15400108', '16270206', '15378796', '15260996', '15556206']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7691800123075747
- 35 USC 102 Novelty (BERT): 0.5318347806970635
- Combined Prediction Score: 0.7454454891465236
- Mean Citation Score: 270.18351399999995
- Max Citation Score: 372.9844
- Similarity Product: 264.7638483168125

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test